| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A multiple testing procedure for clinical trials.
|
Biometrics
|
1979
|
26.80
|
|
2
|
Effects of combination lipid therapy in type 2 diabetes mellitus.
|
N Engl J Med
|
2010
|
16.40
|
|
3
|
THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.
|
Biometrics
|
1965
|
15.61
|
|
4
|
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
|
Lancet
|
2005
|
13.18
|
|
5
|
Estimating the mean and variance from the median, range, and the size of a sample.
|
BMC Med Res Methodol
|
2005
|
10.99
|
|
6
|
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
|
Lancet
|
2020
|
10.16
|
|
7
|
Clinical Characteristics of Coronavirus Disease 2019 in China.
|
N Engl J Med
|
2020
|
9.53
|
|
8
|
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
|
JAMA
|
2020
|
6.59
|
|
9
|
Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010.
|
Am J Med
|
2014
|
5.10
|
|
10
|
Sample sizes for clinical trials with normal data.
|
Stat Med
|
2004
|
3.47
|
|
11
|
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
|
JAMA
|
2016
|
2.05
|
|
12
|
The crossover experiment for clinical trials.
|
Biometrics
|
1980
|
1.51
|
|
13
|
Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
|
J Clin Pharmacol
|
2004
|
1.46
|
|
14
|
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
|
Clin Pharmacol Ther
|
2004
|
1.45
|
|
15
|
Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
|
Clin Pharmacol Ther
|
2000
|
1.24
|
|
16
|
Management of acute and chronic gouty arthritis: present state-of-the-art.
|
Drugs
|
2004
|
1.13
|
|
17
|
Multiple Imputation: A Flexible Tool for Handling Missing Data.
|
JAMA
|
2015
|
1.03
|
|
18
|
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
|
Rheumatology (Oxford)
|
2003
|
1.03
|
|
19
|
A global rank end point for clinical trials in acute heart failure.
|
Circ Heart Fail
|
2010
|
1.01
|
|
20
|
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
|
Clin Pharmacol Ther
|
2003
|
0.96
|
|
21
|
Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.
|
Am J Cardiol
|
2012
|
0.96
|
|
22
|
Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury.
|
Eur Respir J
|
2008
|
0.94
|
|
23
|
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
|
Am J Cardiol
|
2005
|
0.93
|
|
24
|
Pancreatitis associated with simvastatin plus fenofibrate.
|
Ann Pharmacother
|
2002
|
0.89
|
|
25
|
Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
|
Am J Cardiol
|
2010
|
0.89
|
|
26
|
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
|
Clin Ther
|
2009
|
0.87
|
|
27
|
Carryover and the two-period crossover clinical trial.
|
Biometrics
|
1986
|
0.85
|
|
28
|
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
|
J Clin Pharmacol
|
2010
|
0.83
|
|
29
|
Fenofibrate-induced myopathy.
|
Neurol India
|
2004
|
0.82
|
|
30
|
Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.
|
Diabet Med
|
2006
|
0.81
|
|
31
|
Effect of fenofibrate in combination with urate lowering agents in patients with gout.
|
Korean J Intern Med
|
2006
|
0.81
|
|
32
|
Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein.
|
Virology
|
2010
|
0.80
|
|
33
|
Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.
|
Ren Fail
|
2007
|
0.80
|
|
34
|
Rhabdomyolysis associated with gemfibrozil-colchicine therapy.
|
Ann Pharmacother
|
2002
|
0.78
|
|
35
|
PPAR-α activation reduced LPS-induced inflammation in alveolar epithelial cells.
|
Exp Lung Res
|
2015
|
0.77
|
|
36
|
[A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate].
|
No To Shinkei
|
2005
|
0.77
|
|
37
|
Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects.
|
Front Pharmacol
|
2015
|
0.76
|
|
38
|
PPAR-α Agonist WY-14643 Inhibits LPS-Induced Inflammation in Synovial Fibroblasts via NF-kB Pathway.
|
J Mol Neurosci
|
2016
|
0.75
|
|
39
|
Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
40
|
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.
|
Cardiol Res
|
2013
|
0.75
|